Please assess the completion status of the following clinical trial:

Trial Title: An Open Trial of Cysteamine Treatment in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia or schizoaffective disorder~* 18-60 years of age~* Residual symptoms, as defined by both 1 \& 2:~  1. At least one PANSS positive symptom item score \> 4, or at least two items with a score \> 3~ 2. At least one PANSS negative symptom item score \> 4, or at two items with a score \> 3~* No clinically significant change in symptoms for at least one month~* On the same psychotropic medication(s) \> 2 weeks~* Taking a second-generation antipsychotic (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, or clozapine)~* Provision of written informed consent~Exclusion Criteria:~* Meets criteria for current major depressive disorder~* Abnormal hepatic function (AST or ALT \> 2.5 X the upper limit of normal, or bilirubin \> 1.5 X the upper limit of normal)~* Abnormal renal function (BUN or creatinine \> 1.5 X the upper limit of normal)~* Presence of any unstable or untreated medical disorder~* Any history of seizure disorder, HIV, or diagnosis of AIDS~* Any abnormal lab test result that is judged to be clinically significant by the investigators~* Pregnancy, breast feeding, or female and of child-bearing potential who is not using any contraceptive method~* Present danger to self or others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cystagon, Cysteamine Bitartrate (Type: EXPERIMENTAL): We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).